Loading…
Loading…
ELAN does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ELAN and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ELAN and 80,000+ other tickers.
See exactly how ELAN's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ELAN and 80,000+ other tickers.
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and…
Published Data Shows that the Active Ingredient, Lotilaner, in Credelio Quattro: Kills existing black-legged tick (Ixodes scapularis) infestations faster2 than leading competitors, within just 8 hours of treatment.i Kills the lone star tick (Amblyomma americanum) within 12 hours of infestation; achieving the fastest3 initial speed of tick kill compared to the competition.ii Achieves a rapid speed of kill4 on Day 0 and on Day 28, with no statistically significant drop-off in performance at the end of the dosing period.i,ii Outlasts competitors whose speed of kill2,4 performance declined at the end of the month.i,ii INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- When it comes to killing ticks, veterinarians and pet owners want it done fast. New data published in Parasites & Vectors, a leading peer-reviewed publication, demonstrates that Elanco Animal Health's (NYSE: ELAN) Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) kills ticks1 faster2 than leading competitors Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets).i Newly Published Data Found Credelio Quattro: Faster 2 Tick 1 Speed of Kill: Credelio Quattro is the only product proven to significantly reduce black-legged ticks within 8 hours.i Lotilaner, the active ingredient in Credelio Quattro also has the fastest initial tick speed of kill against the lone star tick - in just 12 hours – and sustains the advantage throughout the dosing interval.ii Outperforms the Competition: Outperforms Simparica Trio® (12 hours) and NexGard® Plus (24 hours) at the end of the dosing period (Day 28).i Consistency Over Competitors: Achieves 8-hour speed of kill1 on Day 0 and on Day 28 with no performance drop-off.
Allspring Global Investments Holdings LLC acquired a new position in Elanco Animal Health Incorporated (NYSE: ELAN) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,871,561 shares of the company's stock, valued at approximately $66,390,000. Allspring Global Investments Holdings LLC owned 0.58%
Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
INDIANAPOLIS, July 8, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.
Investors need to pay close attention to ELAN stock based on the movements in the options market lately.